14402 Federal Register / Vol. 80, No. 53 / Thursday, March 19, 2015 / Notices 

MSC 7892, Bethesda, MD 20892, 301–379– 

9351, allen.richon@nih.hhs.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR14–247: 

Pharmacogenetics, Pharmacoepigenetics and 

Personalized Medicine in Children. 

Date: April 16, 2015. 

Time: 10:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Elaine Sierra-Rivera, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6184, 

MSC 7804, Bethesda, MD 20892, 301–435– 

1779, riverase@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Ocular Diseases Pathophysiology 

and Therapeutic Approaches. 

Date: April 16, 2015. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Alessandra C Rovescalli, 

Ph.D., Scientific Review Officer, National 

Institutes of Health, Center for Scientific 

Review, 6701 Rockledge Drive, Rm. 5205 

MSC7846, Bethesda, MD 20892, (301) 435– 

1021, rovescaa@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–13– 

190: Detection of Pathogen Induced Cancer. 

Date: April 17, 2015. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Gagan Pandya, Ph.D., 

Scientific Review Officer, National Institutes 

of Health, Center for Scientific Review, 6701 

Rockledge Drive, Rm. 3200, MSC 7808, 

Bethesda, MD 20892, 301–435–1167, 

pandyaga@mai.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: March 13, 2015. 

Anna Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06268 Filed 3–18–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications, 

contract proposal, and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the grant applications or 

contract proposal, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Clinical Research in HIV/HLB Diseases. 

Date: April 13, 2015. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Dupont Circle Hotel, 1500 New 

Hampshire Avenue NW., Washington, DC 

20036. 

Contact Person: Stephanie L Constant, 

Ph.D. Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6701 Rockledge 

Drive, Room 7189, Bethesda, MD 20892, 301– 

443–8784 constantsl@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Improving Red Blood Cells for Transfusion. 

Date: April 13, 2015. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Room 7198, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Kristin Goltry, Ph.D. 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7198, Bethesda, MD 20892, 301–435–0297, 

goltrykl@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: March 13, 2015. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06269 Filed 3–18–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0620] 

An Interactive Discussion on the 

Clinical Considerations of Risk in the 

Postmarket Environment; Public 

Workshop; Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public workshop; 

request for comments. 

The Food and Drug Administration 

(FDA) is announcing a public workshop 

entitled ‘‘Clinical Considerations of Risk 

in the Postmarket Environment.’’ The 

purpose of this workshop is to provide 

a forum for an interactive discussion on 

assessing changes in medical device risk 

as quality and safety situations arise in 

the postmarket setting when a patient, 

operator, or member of the public uses 

the device. FDA is interested in 

obtaining input from stakeholders about 

assessing risk postmarket when new 

hazards develop in the postmarket 

setting that were not present or not 

known at the time of clearance or 

approval or hazards were anticipated, 

but harm occurs at an unexpected rate 

or in unexpected populations or use 

environments. Comments and 

suggestions generated through this 

workshop will facilitate the assessment 

of risk in postmarket quality and safety 

situations. 

Date and Time: The public workshop 

will be held on April 21, 2015, from 

8:30 a.m. to 5 p.m. 

Location: The public workshop will 

be held at FDA’s White Oak Campus, 

10903 New Hampshire Ave., Building 

31 Conference Center, the Great Room 

(Rm. 1503), Silver Spring, MD 20993– 

0002. Entrance for the public meeting 

participants (non-FDA employees) is 

through Building 1 where routine 

security check procedures will be 

performed. For parking and security 

information, please refer to: http://

www.fda.gov/AboutFDA/

WorkingatFDA/BuildingsandFacilities/

WhiteOakCampusInformation/

ucm241740.htm. 

Contact Person: Jean M. Cooper, 

Center for Devices and Radiological 

Health, Food and Drug Administration, 

10903 New Hampshire Ave., Bldg. 66, 

Rm. 5540, Silver Spring, MD 20993, 

301–796–6141, email: Jean.Cooper@

fda.hhs.gov. 

Registration: Registration is free and 

available on a first-come, first-served 

basis. Persons interested in attending 

this public workshop must register 


Rmajette on DSK2VPTVN1PROD with NOTICES